June 2019

The June Editor-in-Chief letter by Dr. Jason Gallagher tackles the story of Achaogen and what its bankruptcy means for antibiotic development.

Relevant existing reports, though limited, demonstrated positive outcomes and suggest a promising space for pharmacy practice growth in outpatient antimicrobial stewardship.

Being immunocompromised increases risk of rare Mycobacterium tuberculosis epididymo-orchitis.

These tests have the potential to transform patient care and antimicrobial stewardship, but they have not gained widespread acceptance, partly because of uncertainty over how to use them clinically.

A look at up-and-coming HIV drugs in development.

Infections transmitted by these bloodsucking species are on the rise worldwide.

Investigators are dusting off angiotensin II and ascorbic acid for renewed use in treating sepis and septic shock.

For the first time, patients with new HIV diagnoses have a 2-drug regimen option.

This In the Literature piece considers a fixed-dose strategy for administering daptomycin in obese patients.

This In the Literature piece explores if we can mitigate some of the adverse reactions that are being seen in obese patients who receive vancomycin through AUC-dosing.